top of page

Navitoclax in Myelofibrosis: Investigational Treatment by AbbVie

AbbVie, a global research-driven biopharmaceutical company, is conducting the Phase 3 TRANSFORM-2 study to evaluate an investigational drug called Navitoclax in people with Myelofibrosis (MF). This study aims to assess the drug's safety and its impact on spleen volume when administered alongside ruxolitinib, compared to the best available therapy.


AbbVie, a global research-driven biopharmaceutical company, is conducting the Phase 3 TRANSFORM-2 study to evaluate an investigational drug called Navitoclax in people with Myelofibrosis (MF). This study aims to assess the drug's safety and its impact on spleen volume when administered alongside ruxolitinib, compared to the best available therapy.

Want to read more?

Subscribe to gmpnsf.org to keep reading this exclusive post.

10 views0 comments

Comments

Rated 0 out of 5 stars.
Couldn’t Load Comments
It looks like there was a technical problem. Try reconnecting or refreshing the page.
bottom of page